John McMurray, MbChB MD
August 30th, 2014
Will There Be a PARADIGM Shift in Treatment of Heart Failure?
John McMurray, MbChB MD and Milton Packer, MD
John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.
March 15th, 2010
As You Navigate Diabetes Prevention, Should Valsartan Be On Board?
John McMurray, MbChB MD
We welcome John J. McMurray, MD, lead author of the NEJM article on the valsartan component of the NAVIGATOR trial, to answer our questions about this angiotensin-receptor blocker (ARB). We encourage you to ask yours. Background: In the NAVIGATOR trial, 9306 patients with impaired glucose tolerance and established cardiovascular disease or CVD risk factors were randomized, […]
NEJM Journal Watch — Recent Cardiology Articles- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension